Related Experiment Video

Updated: Aug 6, 2026

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Different cell thresholds for commitment to death: a link between carcinogenesis and drug resistance

J A Hickman1

  • 1CRC Molecular and Cellular Pharmacology Group, School of Biological Sciences, University of Manchester, Manchester, UK.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|August 15, 2006
PubMed

Insights

Anticancer drugs trigger genetically controlled cell death (apoptosis) through cell damage. Resistance arises when cells fail to link this damage to death, influenced by gene expression balancing cell survival and death.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Anticancer drugs are known to induce apoptosis (programmed cell death) across various settings.
  • Apoptosis is a genetically regulated cellular mechanism.

Purpose of the Study:

  • To explore the genetic control of drug-induced cell death beyond the drugs' direct mechanisms.
  • To understand the basis of drug resistance related to cell death pathways.

Main Methods:

  • The study implies a conceptual framework rather than specific experimental methods.
  • Focuses on stimulus-response coupling: drug-induced cell damage as stimulus, and cell death as response.

Main Results:

  • Drug-induced cell death is genetically controlled at loci distinct from drug action sites.
  • Failure to link cell damage to cell death constitutes a pleiotropic drug resistance.
  • Cellular thresholds for death engagement vary, influenced by gene expression balancing pro-death and pro-survival signals.

Conclusions:

  • The genetic control of apoptosis by anticancer drugs highlights complex regulatory networks.
  • Pleiotropic drug resistance is linked to the cell's ability to execute genetically programmed death pathways.
  • Gene expression modulation is critical in determining cell fate and therapeutic response.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...